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Given the modest results of ordinary pharmacological 
therapy for osteoarthritis (OA), it was of great interest to 
see the results by Jacquet and colleagues [1] in the 
previous issue of Arthritis Research & Th  erapy. Th  e 
authors tested a new nutraceutical, a food supplement 
marketed as Phytalgic®, in a randomized controlled trial 
(RCT) design. Th   e protocol of this trial was registered in 
ClinicalTrials.gov (NCT00666523) [2]. However, one 
aspect of concern is whether the registration was pre-
speciﬁ  ed. Th   e registration claims that exactly 81 patients 
will be randomly assigned. How can a protocol 
registration foresee a random assignment of 41 patients 
to one group and 40 to the other group when it is a 
consequence of excluding 14 non-eligible patients, as 
presented in the CONSORT (CONsolidated Standards of 
Reporting Trials) Statement?
Th  e authors present data for Phytalgic® [1] which are 
considerably more promising than expected and thus 
should be scrutinized for clinical eﬀ  ect and possible bias 
[3]. According to the authors, Phytalgic® consists of cap-
sules containing ﬁ  sh oils, urtica dioica, zinc, and vitamin 
E. Jacquet and colleagues [1] randomly assigned some 81 
OA patients to receive either Phytalgic® or a matching 
placebo consisting of ‘non-ﬁ  sh oil’. Participants were an 
average of 57 years of age (range of 28 to 84 years) at 
entry, had either knee or hip OA, and were regular users 
of nonsteroidal anti-inﬂ   ammatory drugs (NSAIDs) or 
analgesics. Th  e primary outcome of this 3-month trial 
was use of NSAIDs or analgesics at follow-up. According 
to ClinicalTrials.gov [2], Jacquet and colleagues [1] 
considered the WOMAC (Western Ontario and 
McMaster Universities Osteoarthritis Index) function 
scale a secondary outcome measure, and none of the 
other WOMAC subscales is mentioned in the trial 
registration. In accordance with recent standards on how 
to evaluate the results of OA trials [3,4], Figure 1 presents 
a summary of ﬁ  ndings as generic eﬀ  ect sizes (ESs) based 
on the standardized mean diﬀ   erence, comparing the 
experimental drug (Phytalgic®) with a placebo, for each of 
the continuous outcomes measured on diﬀ  erent scales.
Th   e results of this trial were remarkable. For example, 
the ES for pain reduction was –1.27, which corresponds 
to a very large ES and indicates that Phytalgic® is 76% 
more eﬃ   cacious than intra-articular corticosteroid therapy 
for knee OA [4]. We ﬁ  nd that very hard to believe.
During the last decade, the use of nutraceuticals has 
generated a great deal of interest. In our experience from 
trials [5] and in the results of meta-analyses on ASU 
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A food supplement containing fi  sh oils, urtica dioica, 
zinc, and vitamin E (Phytalgic®) for osteoarthritis (OA) 
has now been tested in a placebo-controlled trial for 
3 months and according to the authors has a very large 
clinical eff  ect, considerably larger than that of any other 
known product. Even experts endorsing nutraceuticals 
for OA symptoms would probably agree that a 
nutraceutical with an eff  ect size above 0.5 is rarely 
seen. Despite our concerns about the fact that trial 
registration took place after the study was completed 
and the likelihood that patients would note the taste of 
fi  sh, a circumstance that would lead to detection bias, 
we consider these data promising though with a high 
risk of bias.
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© 2010 BioMed Central Ltd(avocado-soybean unsaponiﬁ  able) (ES = –0.39) [6], rose-
hip powder (ES = –0.37) [7], and diacerein (ES = –0.24) 
[8], we have never seen anything as eﬃ   cacious  as 
Phytalgic® [3]. Th   e same thing applies in the glucosamine 
area. It is now becoming evident that preparations with 
glucosamine hydrochloride do not ameliorate OA [9], 
and results of trials on diﬀ   erent glucosamine sulfate 
preparations are very conﬂ  icted with lots of inconsistency 
[3,9]. Th   e glucosamine sulfate product from Rottapharm 
Madaus (Monza, Italy) is one exception to this [10]. 
While trials of this particular preparation showed 
promise in the early days with large clinical eﬀ  ects on OA 
in smaller studies, later and presumably more strictly led 
RCTs with less bias have claimed results that are more 
moderate, with an anticipated overall ES on pain of –0.33 
standard deviation units (95% conﬁ  dence interval –0.49 to 
–0.17) [10]. Even OA experts who endorse nutra  ceuticals 
(for example, glucosamine) would probably agree that a 
nutraceutical with an ES above 0.5 is rarely seen.
Th  ere is empirical evidence that OA trials may be 
aﬀ  ected by selection and detection bias [11]. Allegedly, 
few patients noted the taste of ﬁ  sh oil during 12 weeks of 
taking such capsules three times per day. We argue that a 
ﬁ  shy taste in the mouth might certainly cause detection 
bias. Assessment of the trial reporting in terms of risk of 
bias, the use of random assignment, and subsequent 
concealment of allocation would qualify as adequate (that 
is, low risk of selection bias); it seems reasonable that at 
baseline the patients in the study groups were similar 
with respect to prognostic factors. Th  e reporting of 
double-blinding supports a low risk of performance bias 
as the authors state that the manufacturer provided both 
the Phytalgic® and placebo capsules and that it claimed 
that they were identical and indistinguishable. We argue, 
however, that it might be diﬃ   cult to hide the taste of ﬁ  sh 
oil during a 3-month trial, probably as diﬃ   cult as it is to 
hide the taste of ginger [5]. Finally, deviations from 
protocol and loss to follow-up often lead to the exclusion 
of patients after they have been allocated to treatment 
groups, and this may introduce attrition bias [12]. We are 
concerned about the fact that the trial registration was 
done after study completion (April 2008). Th   us, we would 
categorize the risk of attrition bias as being at best 
unclear as there is a possibility that some patients were 
excluded from the analyses. Although the authors 
performed their analyses according to the intention-to-
treat principle on what they claim is the correct sample 
size, we worry about the fact that the attrition rate was 
10% (4/40) in the placebo group, whereas only 2% (1/41) 
withdrew from Phytalgic®.
With that said, we are now faced with some very 
promising results of Phytalgic® [1], and further experience 
is needed to show whether this product on a larger scale 
will become a relevant treatment option for OA [3,7]. As 
previously pointed out, the largest studies and the studies 
that are strictly monitored by good clinical practices are 
Figure 1. Forest plot of outcomes showing eff  ect sizes comparing Phytalgic® with placebo in osteoarthritis patients, presented as 
standardized mean diff  erences. CI, confi  dence interval; NSAID, nonsteroidal anti-infl  ammatory drug; SD, standard deviation.
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Page 2 of 3usually directly sponsored by the product manufacturers 
[10]. A fully independent analysis of a product like 
Phytalgic® would require funding from oﬃ   cial organiza-
tions (for example, the National Institutes of Health, 
which indeed needs reshuﬄ   ing of its priorities). Th  ese 
initial data on Phytalgic® would seem to justify such 
action. If these data are conﬁ  rmed, a goldmine has been 
struck and OA therapy is in for dramatic changes.
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